Navigation Links
CryoLife Announces First European Implant Of HeRO Graft
Date:7/31/2013

ATLANTA, July 31, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that the first European clinical implant of the Company's HeRO (Hemodialysis Reliable Outflow) Graft was performed at the University of Leuven Hospital in Belgium.  The procedure was performed by Professor Inge Fourneau, a vascular surgeon, and Professor Sam Heye, an interventional radiologist.

Professor Fourneau and Professor Heye commented, "It is exciting to be the first hospital in Europe to offer the innovative benefits of the HeRO Graft to dialysis patients with end-stage renal disease in our local community.  Based on the clinical results to-date in the U.S., we believe the HeRO Graft will reduce the rate of infection as compared to tunneled dialysis catheters and improve patient quality of life."

CryoLife received CE Mark for the HeRO Graft in June 2013.  Professor Fourneau and Professor Heye will collaborate with the nephrologist team at the University of Leuven.  CryoLife expects to conduct a controlled market introduction of the HeRO Graft during the second half of 2013, followed by a broader European launch in 2014.  

Steven G. Anderson, chairman, president and CEO of CryoLife, said, "We are pleased to begin commercialization of the HeRO Graft in Europe and would like to thank Professor Fourneau and Professor Heye for performing the procedure.  Over the remainder of the year we will train additional physicians on the procedure, which will support a broader launch in Europe beginning in 2014.  We continue to believe the HeRO Graft represents a significant opportunity to provide a better dialysis access option for patients with end-stage renal disease and that it will be a growth driver for the Company."

About the HeRO Graft

The HeRO Graft received its initial FDA 510(k) clearance in 2008 and initial CE Mark approval in 2011.  It is indicated for catheter dependent ESRD patients on long-term hemodialysis who have exhausted all other access options, such as AV fistulas and grafts (AVFs and AVGs). Prior to the introduction of the HeRO Graft, the only option for these patients was access through percutaneous tunneled dialysis catheters (TDCs), which are higher cost, have high infection rates, limit a patient's lifestyle, and foster central venous stenosis, or narrowing.  The HeRO Graft overcomes the limitations of TDCs by providing a completely subcutaneous graft that functions like a regular access graft during dialysis and provides superior blood flow and a 69 percent reduction in bacteremia (bacteria in the blood) compared with TDCs. HeRO Graft is the only subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with central venous stenosis.

The HeRO Graft has been implanted in more than 6,000 patients to date and is supported by nearly 130 published clinical studies and presentations.  The product has established reimbursement rates in the U.S., with reimbursement codes that are endorsed by the Society for Vascular Surgery and the American Medical Association.  For more information on the HeRO Graft, visit www.herograft.com.  For additional information about CryoLife, visit the company's Web site: www.cryolife.com.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations.  These statements include those regarding our belief that HeRO Graft will be a growth driver for the Company.  The impact of HeRO Graft upon our growth is subject to a number of risks and uncertainties, including that physicians and patients may not accept HeRO Graft as a viable treatment option, regulators could withdraw existing approvals or impose additional conditions for the use of  HeRO Graft, future implants may not be successful or complications could arise subsequent to implant, economic conditions in the EU could impact the decision to utilize HeRO Graft based on its cost, competing products may prove more effective or cost less, and the recent inability of the Company to import tissue into the EU could impact decisions to utilize HeRO Graft.  CryoLife is also subject to the general risks associated with our business, including the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2012 and subsequent filings.  CryoLife does not undertake to update its forward-looking statements.

Contacts:

CryoLife

D. Ashley Lee

Executive Vice President, Chief Financial Officer
and Chief Operating Officer
Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

 


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Second Quarter Revenues
2. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
3. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
4. CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
6. CryoLife Receives FDA Clearance For Next Generation HeRO Device
7. CryoLife Expands Stock Repurchase Program
8. CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
9. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Receives Expanded Indication for BioFoam in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really works. ... be incorporated into the post-surgical treatment plans of a variety of other procedures including, ... is very effective for bruising and causes a rapid resolution of bruising and inflammatory ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Dr. Seema ... joins Evans Dermatology in the South Lamar location as of July 13, 2016. , ... Medical School. As a medical student, she regularly volunteered at the Agape Clinic serving ...
Breaking Medicine News(10 mins):